Leukemia Research
Volume 25, Issue 12 , Pages 1097-1098 , December 2001

Autoimmune hemolytic anemia during α-interferon treatment in a patient with chronic myelogenous leukemia

Received 1 November 2001

References 

  1. Quesada JR, Talpaz M, Rios A, Kurzock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J. Clin. Oncol. 1986;4:234–243
  2. Andriani A, Bibas M, Callea V, et al.  Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases. Haematologica. 1996;81:258–260
  3. Conlon KC, Urba WJ, Smith JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990;65:2237–2242
  4. Barbolla L, Paniagua C, Outeirino J, Prieto E, Sanchez Fayos J. Haemolytic anaemia to the alpha-interferon treatment: a proposed mechanism. Vox Sang. 1993;65:156–157
  5. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alpha therapy in chronic myelogenous leukemia. J. Clin. Oncol. 1995;13:2401–2407
  6. Ballester OF, Spiers ASD, Grattan J. Autoimmune hemolytic anemia (AIHA) accompanying treatment with alpha-interferon (IFN) in a patient with chronic granulocytic leukemia (CGL). Blood. 1989;74(Suppl.):352

PII: S0145-2126(01)00093-5

Leukemia Research
Volume 25, Issue 12 , Pages 1097-1098 , December 2001

Article Tools